What Can Be Done for Scar Tissue on the Heart?

Cardiac scar tissue cannot yet be reversed with any single treatment, but a growing range of therapies can limit its consequences, slow further damage, and in some cases modestly reduce the scar itself. After a heart attack or other cardiac injury, dead muscle is replaced by stiff, fibrous tissue over several weeks, and that scar does not contract or conduct electrical signals the way healthy heart muscle does.¹ The practical question for most people is not whether the scar can be erased but what combination of medications, procedures, rehabilitation, and emerging technologies can restore as much heart function as possible.

Why Scar Tissue Forms and Why It Matters

When heart muscle cells die, whether from a blocked coronary artery, a viral infection, or another cause, the body patches the wound with collagen-rich scar tissue. Unlike skeletal muscle, the adult human heart has almost no ability to regrow lost muscle cells. The repair job is handled largely by fibroblasts, cells that multiply rapidly at the injury site and lay down a scaffolding of collagen fibers. Some of these fibroblasts transform into a more aggressive form called myofibroblasts, which ramp up production of structural proteins like collagen and fibronectin.² The resulting scar keeps the heart wall intact and prevents rupture, so it is not purely harmful. But it is stiff, electrically inert, and permanently weakens the heart’s pumping ability in proportion to its size.

Enzymes called matrix metalloproteinases (MMPs) also surge after an infarction, remodeling the collagen framework throughout the heart, not just in the injured zone.³ The wound-healing process involves overlapping phases of inflammation, granulation tissue formation, scar deposition, and broader ventricular remodeling, each governed by a shifting balance between MMPs and their natural inhibitors.⁴ This remodeling can stretch the scarred wall, thin healthy tissue, and enlarge the left ventricle, a process that progressively worsens heart failure if left unchecked.

Detecting and Measuring the Scar

Before deciding on treatment, doctors need to know how much scar is present and where it sits. The reference technique for this is a cardiac MRI with a gadolinium-based contrast agent, a procedure commonly called late gadolinium enhancement (LGE) imaging. A small dose of contrast is injected, and images are taken about ten to fifteen minutes later. Healthy muscle washes the gadolinium out quickly, but scar tissue retains it, lighting up bright on the scan.⁵ The pattern of enhancement tells the cardiologist a lot: a scar that follows a coronary artery’s territory points to a prior heart attack, while a patchy or mid-wall pattern suggests a non-ischemic cause like myocarditis or a cardiomyopathy.

Measuring exactly how much scar is present remains trickier than it sounds. Several quantification approaches exist, from manual tracing to automated thresholding algorithms, and they do not always agree with each other. In many clinical settings, the scar is still evaluated by eye rather than by precise measurement.⁶ Newer dark-blood LGE sequences improve the contrast between scar and surrounding tissue, making automated measurement more reliable across different scar patterns.⁷ The size and location of the scar guide nearly every treatment decision that follows.

Standard Medications That Slow Remodeling

The first line of defense against worsening scar-related damage is pharmacological. ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists have decades of evidence behind them for slowing ventricular remodeling after a heart attack. They do not dissolve existing scar, but they reduce the mechanical and hormonal stress that drives the heart to enlarge around the scar. Newer agents like sacubitril-valsartan (an ARNI) and SGLT2 inhibitors have further improved outcomes in heart failure. In essence, these medications protect the surviving heart muscle and limit the scar’s downstream effects on pumping function.

Researchers have also explored drugs that directly target the fibrotic process. Inhibiting certain signaling pathways, such as the TGF-β pathway through a molecule called ALK5, has been shown in laboratory studies to convert activated myofibroblasts from failing human hearts back toward a quieter state, which could theoretically reduce ongoing fibrosis.⁸ None of these targeted anti-fibrotic drugs have reached routine clinical use for the heart yet, but the pipeline is active, with approaches spanning small molecules, peptides, and microRNA-based interventions.⁹

Dealing With Arrhythmias From Scar Tissue

One of the most dangerous consequences of cardiac scar is its ability to generate life-threatening heart rhythm disturbances. Electrical signals traveling through the heart can get trapped in narrow corridors of surviving muscle threaded through the scar, creating loops that drive ventricular tachycardia (VT). These reentry circuits contain slow-conduction zones that sustain the abnormal rhythm.¹⁰

Catheter ablation is the primary procedural treatment for scar-related VT. A thin catheter is threaded into the heart, and the electrophysiologist uses detailed electrical maps to identify the critical channels within the scar. Radiofrequency energy or cryotherapy is then applied to burn or freeze those channels, breaking the circuit. Mapping technology has grown more sophisticated: newer techniques using repolarization time maps can pinpoint ablation targets even when traditional mapping landmarks are ambiguous, with studies finding that most successful ablation sites correspond to areas of short repolarization time near the circuit’s exit point.¹¹

For patients at high risk of sudden cardiac death from scar-related arrhythmias, an implantable cardioverter-defibrillator (ICD) serves as a safety net, delivering a shock if a lethal rhythm occurs. Ablation and ICDs are complementary: ablation reduces how often dangerous rhythms happen, while the ICD is there if they happen anyway.

Surgical Approaches to Scarred Ventricles

When a large area of scar causes the heart wall to bulge outward (a ventricular aneurysm), surgery can physically reshape the chamber. The classic operation, called surgical ventricular reconstruction (SVR), involves opening the heart, excluding the scarred segment, and rebuilding the ventricle into a more normal shape, usually during the same operation as coronary artery bypass grafting (CABG). SVR does shrink the heart’s volume significantly, but a major randomized trial found that adding SVR to bypass surgery did not improve survival or reduce hospitalizations compared to bypass surgery alone, despite reducing the ventricle’s end-systolic volume by about 19% versus 6% with bypass alone.¹² That result cooled enthusiasm for routine SVR, though selected patients with very large aneurysms may still benefit.

Less invasive alternatives have emerged. The Revivent TC system, for instance, uses anchoring devices threaded through the chest wall and the heart to cinch the scarred portion together without opening the chest or stopping the heart.¹³ These catheter-based devices are still being evaluated in larger trials, and their long-term results are not yet settled.

Cardiac Rehabilitation and Exercise

Exercise after a heart attack might seem counterintuitive when part of the heart is scarred, but structured cardiac rehabilitation is one of the best-supported interventions for improving how a scarred heart functions. Exercise training has been shown to favorably alter post-infarction remodeling through several pathways, including dialing down the overactive renin-angiotensin-aldosterone system, rebalancing matrix metalloproteinases and their inhibitors, reducing oxidative stress, and boosting the growth of new small blood vessels in the heart.¹⁴

There is even preliminary evidence that vigorous exercise may reduce the scar itself. A case report documented a decrease in infarct scar size on successive cardiac MRI scans in a patient doing high-intensity aerobic interval training after a heart attack.¹⁵ That finding comes from a single case, so it cannot be generalized, but it aligns with a broader body of evidence suggesting exercise can positively influence the wound-healing process. Cardiac rehabilitation programs also incorporate risk-factor management and medication optimization, both of which contribute to long-term outcomes.¹⁶

Stem Cell Therapy

Injecting stem cells into or around a cardiac scar has been tested in hundreds of clinical trials over the past two decades. The idea is appealing: deliver cells that can grow into new heart muscle and replace the scar. In animal models, mesenchymal stem cells (MSCs) have consistently reduced fibrosis, stimulated new blood-vessel growth, and improved the structure and function of remodeled ventricles.¹⁷ The mechanism appears to work mostly through signaling rather than the stem cells literally turning into heart muscle. The transplanted cells release molecules that stimulate the heart’s own anti-fibrotic and regenerative responses.¹⁸

In human trials, though, results have been underwhelming. Most studies have been small, and the outcomes are generally described as inconclusive.¹⁹ One reason for the gap between animal and human results is that injected cells survive poorly in the hostile environment of a fresh or chronic infarct. The realization that stem cells help primarily through their secreted factors has opened a parallel research track: cell-free therapy using only the exosomes or conditioned media from stem cells, which could deliver the beneficial signals without the complications of live-cell transplantation.

Engineered CAR T Cells Against Fibrosis

Perhaps the most striking experimental approach borrows from cancer immunotherapy. Chimeric antigen receptor (CAR) T cells are immune cells engineered to recognize and destroy a specific target. Researchers have directed them against fibroblast activation protein (FAP), a marker found on the activated fibroblasts responsible for cardiac scarring. In mice, adoptive transfer of these FAP-targeting CAR T cells significantly reduced cardiac fibrosis and restored heart function after injury.²⁰

A major concern with traditional CAR T cells is that they persist in the body and could attack healthy tissues that express even low levels of the target protein. A newer approach sidesteps this problem by generating temporary CAR T cells directly inside the body. Modified mRNA encoding the CAR is packaged into lipid nanoparticles that home to T cells after a simple injection. In a mouse model of heart failure, this produced short-lived but effective anti-fibrotic CAR T cells that reduced fibrosis and improved cardiac function, then disappeared.²¹ A separate study identified CD248 as another fibroblast target, showing that either a monoclonal antibody or CAR T cells directed against it could reduce fibrosis and dysfunction in the heart.²² All of this remains preclinical, but the pace of development has been rapid.

Cardiac Patches and Biomaterials

Instead of injecting individual cells into a scar, another strategy is to lay a patch over or into the damaged area. These cardiac patches are typically made from biocompatible scaffolds, sometimes seeded with cardiomyocytes or loaded with growth factors, and are designed to provide mechanical support, deliver therapy locally, and restore some electrical conductivity to the infarcted zone.²³ Decellularized heart tissue from human or animal donors has also been used as a scaffold, promoting regeneration in laboratory and animal studies.²⁴

One particularly promising design uses injectable, electrically conductive scaffolds made from modified elastin, gelatin, and carbon nanotubes. In both rats and minipigs with heart attacks, these patches improved the heart’s pumping ability within four weeks, whether they were implanted alone or seeded with cardiomyocytes.²⁵ The injectable format is significant because it avoids open-heart surgery for delivery. None of these patches are in routine clinical use for scar replacement, but the technology has reached large-animal testing, a necessary step before human trials.

Direct Reprogramming of Scar Into Muscle

The boldest concept in the field aims to convert the scar’s own fibroblasts directly into beating heart muscle cells, skipping the stem-cell step entirely. Scientists have shown in laboratory settings that delivering a cocktail of transcription factors can push fibroblasts toward a cardiomyocyte-like fate. The efficiency remains low, which is one of the biggest hurdles, and there are unresolved questions about whether the reprogrammed cells function well enough to integrate electrically with the surrounding heart.²⁶ If perfected, though, this approach would be transformative: the raw material for repair is already sitting in the scar, waiting to be repurposed.

Blood Biomarkers for Tracking Fibrosis

A practical challenge with all of these therapies is knowing whether they are working without repeated MRI scans. Blood biomarkers of fibrosis, such as fragments of collagen turnover, have been proposed as a simpler way to monitor the amount of scar tissue in the heart. In practice, most of these circulating markers have not been convincingly shown to reflect what is actually happening in the heart muscle, as opposed to fibrosis elsewhere in the body.²⁷ Cardiac MRI remains the best tool for tracking scar size over time, with blood tests serving as rough supplements rather than replacements.

The Gut-Heart Connection

An unexpected thread in recent cardiac fibrosis research points to the gut. Certain metabolites produced by gut bacteria, most notably trimethylamine N-oxide (TMAO), appear to actively promote cardiac scarring. In animal studies, TMAO accelerated the transformation of fibroblasts into myofibroblasts and worsened fibrosis after a heart attack by ramping up the TGF-β signaling pathway.²⁸ TMAO levels rise with diets high in red meat, eggs, and certain other animal products, because gut bacteria convert choline and carnitine from those foods into the precursor molecule.

Broader research on the gut-heart axis suggests microbial metabolites influence inflammation, blood-vessel health, and even cardiomyocyte survival after injury, with germ-free mouse models establishing causal links between specific bacterial populations and heart repair outcomes.²⁹ Some of these effects appear to operate through epigenetic changes, where microbial metabolites alter how genes governing inflammation and fibrosis are switched on or off in heart cells.³⁰ This does not mean a probiotic will cure cardiac fibrosis, but it opens the possibility that dietary or microbiome-targeted interventions could one day complement standard treatments.

Lessons From Animals That Regenerate Their Hearts

Zebrafish can regrow up to 60% of their heart muscle within one to two months after injury. Newts and axolotls accomplish similar feats over a somewhat longer timeframe.³¹ These animals initially form scar tissue much as mammals do, but then actively resolve it, replacing the collagen with new muscle. Studies in zebrafish have found that a specific population of anti-inflammatory macrophages is necessary for the scar-resolution phase, while pro-inflammatory macrophages promote initial scar deposition.³²

Mammals are not entirely locked out of this trick. Newborn mice can regenerate heart tissue after surgical resection during the first day of life, but lose that ability by the end of the first week as cardiomyocytes exit the cell cycle and stop dividing.³³ A family of small regulatory RNA molecules called the miR-15 family has been implicated in shutting down this regenerative window.³⁴ Understanding what switches regeneration off in mammals is one of the most active areas of cardiovascular research, because reactivating even a fraction of that neonatal capacity in adults could fundamentally change how we treat cardiac scar tissue.